The protein encoded by the murine double minute 2 (Mdm2) gene inactivates the function of the tumor suppressor p53. The targeted expression of the mdm2 transgene (BLGmdm2) to the mammary epithelium disrupts the cell cycle, causing multiple rounds of DNA synthesis without proper cell division and consequently poor mammary gland development. These phenotypes in the mammary epithelia of the transgenic mice are not dependent on either p53 or the transcription factor E2F1, as mice null for these genes carrying the BLGmdm2 transgene exhibit similar defects to mice carrying the BLGmdm2 transgene alone. p19ARF, an alternative splice product of the INK4a/ARF locus, has been shown to interact directly with MDM2. Therefore, BLGmdm2 transgenic mice null for p19ARF were created to gain insight into the mechanism by which mdm2 overexpression disrupts the cell cycle. The BLGmdm2 phenotype in the absence of p19ARF was worse than BLGmdm2 mice and visible as early as day 15 of pregnancy. By day 5 of lactation the phenotype was very pronounced. Histological analysis of the mammary gland showed a decrease in ductal branching, smaller and fewer lobuloalveolar structures, and a decrease in luminal secretions. Multinucleated and enlarged cells were present due to continued replication in the absence of cytokinesis. Thus, the absence of p19ARF in this in vivo system enhanced the defect caused by mdm2 overexpression.
Introduction
One well-characterized function of the murine double minute 2 (MDM2) protein is as an inhibitor of the tumor suppressor p53 (Momand et al., 1992) . MDM2 inhibits the transcriptional activity of p53 thus interfering with the ability of p53 to activate downstream target genes (Chen et al., 1993) . MDM2 is an E3 ubiquitin ligase and it targets p53 for rapid degradation by ubiquitin-mediated proteolysis (Kubbutat et al., 1997; Haupt et al., 1997; Honda et al., 1997) . Studies performed in mice underline the functional relationship between these two proteins. The deletion of mdm2 in mice results in embryonic lethality at 5.5 d.p.c. This lethality is completely rescued in a p53-null background (Montes de Oca Luna et al., 1995; Jones et al., 1995) emphasizing the important interaction of MDM2 and p53 in vivo.
Mutations that inactivate p53 are common in tumors. Yet another mechanism of derailing p53 function is by over production of its inhibitor MDM2. MDM2 is ampli®ed in 30% of human sarcomas (Oliner et al., 1992; Leach et al., 1993; Momand and Zambetti, 1997) and in some glioblastomas and breast carcinomas (Nakayama et al., 1995; Marchetti et al., 1995; McCann et al., 1995) . MDM2 levels are high in other tumors independent of ampli®cation (Evans et al., 2001) . Some of these tumors retain a wild-type p53 gene, providing evidence for functional inactivation of p53. However, some of the tumors with high levels of MDM2 have mutant p53, opening up the possibility that MDM2 may have additional oncogenic functions. Both mutation of p53 and over production of MDM2 must be advantageous for tumor growth. In support of this hypothesis, studies in mice indicate that overexpression of mdm2 produces a higher incidence of sarcomas (38%) as compared to p53-null mice (9%) (Jones et al., 1998) . Thus, MDM2 may have functions independent of p53 that may provide an additional growth advantage.
Another potential target in MDM2 oncogenesis is p19ARF (alternative reading frame). p19ARF is an alternative splice product of the INK4a locus. The INK4a locus contains two unique ®rst exons, 1a and 1b, each with its own promoter and transcriptional start site. Alternative promoter usage results in two distinct transcripts (Mao et al., 1995; Stone et al., 1995; Quelle et al., 1995; Serrano et al., 1996) , encoding distinct proteins through alternate reading frames. The 1a transcript encodes p16 ink4a , while the 1b transcript encodes p19ARF. Upon induction by cellular oncogenes, p19ARF interacts with MDM2 which ultimately results in stabilization and activation of p53 (deStanchina et al., 1998; Pomerantz et al., 1998; Zhang et al., 1998; Zindy et al., 1998) .
Mice lacking p19ARF develop tumors as early as 2 months after birth and survived up to 38 weeks of age (Kamijo et al., 1997 (Kamijo et al., , 1999 . The tumor spectrum in these mice includes sarcomas (43%) and lymphomas (29%) (Kamijo et al., 1999) . Mutations in p19ARF occur in a few human tumors in the absence of p16 ink4a mutations (Ruas and Peters, 1998) . Some of these have functional signi®cance (Zhang and Xiong, 2000) . Together, these data indicate p19ARF functions as a tumor suppressor. Additionally, p19ARF-null mouse embryo ®broblasts (MEFs) grown in culture have increased proliferative capability compared to MEFs that are wild-type for p19ARF and these null MEFs have decreased levels of wild-type p53 (Kamijo et al., 1997) . These data indicate that the deletion of p19ARF disrupts the MDM2-p53 balance increasing the levels of available MDM2 to inactivate p53.
Transgenic mice developed to examine the role of mdm2 in vivo have shown that mdm2 overexpression in the mammary epithelium of female mice causes poor mammary gland development and cell cycle defects (Lundgren et al., 1997) . The b-lactoglobulin promoter was used to drive expression of mdm2 (BLGmdm2) speci®cally to the epithelial cells of the mammary gland. Abnormalities include loss of lobulo-alveolar structures, fewer epithelial cells, and large multinucleated cells. An increase in DNA synthesis is observed during lactation, when the gland is normally terminally dierentiated and undergoing little mitotic activity. The epithelial cells are also polyploid with DNA contents of 8N and greater. Thus, increased DNA synthesis and ploidy suggest the overexpression of mdm2 uncouples S phase from mitosis. This BLGmdm2 transgenic phenotype is independent of p53, in that the phenotype did not change in a p53 null background (Lundgren et al., 1997) .
Since p19ARF directly binds to MDM2, we hypothesized that the loss of p19ARF would aect the BLGmdm2 transgenic phenotype. We utilized this mouse model to test whether the p19ARF-MDM2 interaction is responsible for the cell cycle defects that occur when mdm2 is overexpressed in the mammary gland. We generated mice overexpressing mdm2 and lacking p19ARF. Mammary glands from day 15 of pregnancy and day 5 of lactation were analysed by histology. We found that the BLGmdm2 transgenic mice lacking p19ARF exhibited an even worse phenotype with further loss of lobulo-alveolar structures and fewer epithelial cells. These cells continued to replicate DNA at a time when they should have dierentiated. Thus, in the absence of p19ARF, more MDM2 is free to target other proteins for degradation.
Results
The loss of p19ARF reduces alveolar branching in BLGmdm2 trangenic mice
To examine the interaction of p19ARF and MDM2 in vivo, BLGmdm2 mice expressing high levels of mdm2 in the mammary gland were mated with p19ARF-null mice in order to generate transgenic mice with increased levels of MDM2 lacking p19ARF. Mammary gland development was examined during pregnancy and lactation.
Histological analysis of the mammary gland of the BLGmdm2/p19ARF-null mice ®rst showed dierences from the BLGmdm2 transgenic and normal mice during pregnancy (Figure 1 ). During the ®rst part of pregnancy in normal mammary gland development, there is substantial mitotic activity. Mitotic activity becomes infrequent by about day 15 of pregnancy (Rugh, 1968) at which point the ducts dierentiate into alveoli. In the BLGmdm2/p19ARF-null mice, examined at day 15 of pregnancy, we observed a reduction in the number of alveoli branching from the ductal tree compared with normal, p19ARF-null, and BLGmdm2 transgenic mice (Figure 1) .
The phenotype worsened when examined during lactation. At day 5 of lactation, BLGmdm2 transgene expression, as measured by RNA levels, peaked and the transgenic phenotype was most apparent (Lundgren et al., 1997) . As with the BLGmdm2 transgenic mice, the BLGmdm2 transgenic mice heterozygous or null for p19ARF displayed low milk production requiring the use of foster pups to allow for continued nursing. Moreover, some of the BLGmdm2/p19ARF-null females, but neither of the other two genotypes, displayed even more lactating diculties, with foster pups dying prior to day 5 of lactation.
Histologically, at day 5 of lactation, the wild-type glands showed expanded lobulo-alveoli that encompassed the entire section of the gland with very little residual fat pad (Figure 2 ). In the p19ARF-null mammary glands, there were more lobulo-alveoli than in normal glands re¯ecting the role of p19ARF in proliferation. In contrast, in the BLGmdm2 mice there . There is less branching of the ductal tree in the BLGmdm2/p19ARF 7/7 compared to the wild-type and the BLGmdm2. Magni®cation 2006 were fewer lobulo-alveolar structures and reduced milk production, as previously reported (Lundgren et al., 1997) . In the BLGmdm2/p19ARF-null gland a more dramatic eect was observed. There were even fewer lobulo-alveolar structures; they were smaller and each one had fewer epithelial cells. Large areas of fat pad were very evident. Less than half of the ®eld analysed consisted of lobulo-alveolar structures. A loss in luminal secretions with less lumina surrounding the epithelial cells was also evident, making the epithelial cells appear¯atter. It is worth noting that these histological dierences were incompletely penetrant, in that 71% of the BLGmdm2/p19ARF-null animals analysed displayed these more severe defects.
The lobulo-alveolar structures present during lactation were counted in order to quantitate the dierences ( Figure 3 ). The p19ARF-null mice showed the highest average of lobulo-alveolar structures. The number was lower in the BLGmdm2 mice and still lower in the BLGmdm2/p19ARF-null mice. The decrease in lobuloalveolar structures in BLGmdm2/p19ARF-null was statistically dierent from all the other genotypes examined.
To con®rm MDM2 expression in the BLGmdm2/ p19ARF-null mice, we analysed protein expression by immunohistochemistry and Western blot analysis. A polyclonal rabbit anti-mouse MDM2 antibody (9313) showed high expression of MDM2 in the BLGmdm2 transgenic control at day 5 of lactation ( Figure 4a ). The BLGmdm2/p19ARF-null gland also showed similarly high levels of MDM2 expression. Due to the heterogeneity of the mammary gland, staining was not uniform; some nuclei of the epithelial cells stained darker than other cells. No MDM2 protein was detected in the wild-type or p19ARF-null glands. As a control for antibody speci®city, the spleen (which normally produces detectable levels of MDM2) of a mdm2/p53 double null mouse (®xed and prepared in the same way) showed no staining.
To further analyse MDM2 protein expression, Western analysis was performed on mammary epithelial cells isolated from mammary glands using a MDM2-speci®c polyclonal antibody (Figure 4b ). There are very low levels of MDM2 detectable in both the wild-type and the p19ARF-null cells. The BLGmdm2 cells showed increased levels of MDM2 expression. The BLGmdm2/p19ARF-null cells showed the same level of protein expression as the BLGmdm2 cells. The similar levels of tubulin indicate that equivalent amounts of protein were loaded in each lane.
Cell cycle analysis in BLGmdm2 transgenic mice lacking p19ARF
The overexpression of mdm2 in the mammary gland results in cell cycle defects (Lundgren et al., 1997) . These cells are undergoing multiple rounds of DNA replication without cytokinesis. The cell cycle defects in mice overexpressing mdm2 and lacking p19ARF were further addressed by analysing apoptosis and DNA synthesis during lactation. TUNEL assays were essentially negative in mice of all genotypes (Table 1) . Bromodeoxyuridine (BrdU) incorporation assays showed less that 1% BrdU incorporation in wild-type and p19ARF-null glands, indicating that the epithelial cells in these glands were not undergoing DNA synthesis ( Figure 5 and Table 2 ). In both the BLGmdm2 and the BLGmdm2/p19ARF-null mice, BrdU incorporation was very high, indicating increased DNA synthesis in these glands at a time when the normal gland has ceased proliferation. Figure 3 Analysis of the average number of lobulo-alveoli at day 5 of lactation. The total average of lobulo-alveolar structures counted from the abdominal mammary gland at 1006magni®ca-tion. n=4 for wild-type, n=4 for p19ARF
, n=5 for BLGmdm2, and n=5 for BLGmdm2/p19ARF
. There is a decrease in the total average number of lobulo-alveoli structures in the BLGmdm2/p19ARF 7/7 compared to the wild-type controls and the BLGmdm2
Multinucleated cells and cells with giant nuclei were observed in the BLGmdm2 transgenic mice (Lundgren et al., 1997) . To address the question of what eect the loss of p19ARF would have on this cell cycle phenotype, hematoxylin and eosin (H and E) stained sections were analysed (Table 3) . Some multinucleated cells contained more than two nuclei, and not all were of equal size, indicating an unequal distribution of DNA. The number of cells with multiple and giant nuclei was higher in the BLGmdm2/p19ARF-null mice as compared to BLGmdm2. These data provide further support that the defect in BLGmdm2 transgenic mice is worse in the absence of p19ARF. 
Discussion
The loss of p19ARF enhances the defects of BLGmdm2
To examine the interaction of p19ARF and MDM2 in vivo, mice that overexpress mdm2 and lack p19ARF were generated. During pregnancy and lactation, the absence of p19ARF enhanced the cell cycle defects produced by mdm2 overexpression. The ®rst sign of a defect in mammary gland development was detected at day 15 of pregnancy when BLGmdm2/p19ARF-null mice showed a reduction in the branching of alveoli from the ductal tree. By day 5 of lactation, the phenotype was more enhanced with an increased loss of lobulo-alveolar structures.
This increased loss caused severe lactating diculties, with the foster pups dying due to starvation. Two of the BLGmdm2/p19ARF-null females, lost all foster pups before day 5 of lactation, and could not be used in the study. This was not seen in the BLGmdm2 or p19Arf-null mice. These observed lactating diculties correspond with the reduction in the number of lobuloalveolar structures. These data suggest that the interaction of MDM2 and p19ARF has functional consequences to mammary gland development in vivo.
Other factors that interact with MDM2 could be involved in this phenotype. The overexpression of mdm2 in the mammary epithelium results in increased DNA synthesis and increased ploidy (Lundgren et al., 1997) . Studies have already been done to analyse the eect of MDM2-binding proteins p53 and E2F1 on the BLGmdm2 transgenic phenotype (Lundgren et al., 1997; Reinke et al., 1999) . The data showed no dierence in the phenotype between BLGmdm2 and BLGmdm2 lacking p53 or E2F1, suggesting that the phenotype is independent of these two genes. In the present study, loss of p19ARF enhanced the phenotype through an increase in levels of free MDM2, an increase brought about by the loss of interactions with p19ARF. In addition, interaction of MDM2 with Rb, ribosomal L5, TATA-binding protein, and MTBP have been reported (Xiao et al., 1995; Marechal et al., 1994; Boyd et al., 2000) , but the functional signi®cance of these interactions remains to be seen.
Interestingly, mice null for p19ARF alone also showed problems in proper mammary gland development. There was an increase in the number of lobuloalveolar structures compared to wild-type, suggesting that the loss of p19ARF results in an increase in cell number. This result is in con®rmation with a previous report where p19ARF-null MEFs accumulated more cells and proliferated at a faster rate compared to p19ARF wild-type MEFs (Kamijo et al., 1997) .
MDM2 functions as an E3 ubiquitin ligase both for itself and for p53 (Honda et al., 1997; Fuchs et al., 1998) . No other substrates have thus far been identi®ed. Since the phenotypes in these mice were p53 independent, it appears likely that there are other targets of ubiquitination by MDM2. This unknown substrate may be involved in coordinating the S-to Mphase transition, the loss of which may lead to multiple rounds of replication without cytokinesis.
One possible factor that ®ts this description is Geminin. Geminin is an inhibitor of DNA replication and is degraded during mitosis (McGarry and Kirschner, 1998) . Geminin is degraded by ubiquitindependent proteolysis by APC (anaphase promoting factor), which also degrades the B-type cyclins (McGarry and Kirschner, 1998) . McGarry and Kirschner have proposed a model which suggests that the function of Geminin is to prohibit the initiation of DNA replication at an inappropriate time during the cell cycle. Geminin is then degraded at the metaphaseanaphase transition in order to allow for DNA replication in the next cycle. This raises the possibility that increased levels of MDM2 in the BLGmdm2 mice targets Geminin for degradation, thus allowing the cells to continually initiate DNA replication.
In Saccharomyces cerevisiae, the Clb ± Cdk kinase complexes are necessary for preventing re-replication by inhibiting the transition of replication origins to a pre-replicative state (Dahmann et al., 1995) . It has also been discovered that yeast containing mutations in SIM1 and SIM2 undergo additional rounds of DNA replication without mitosis (Dahmann et al., 1995) . Mouse homologs of these factors would be worth investigating to unveil the mechanism by which such abundant amounts of MDM2 in the cell leads to increased cell cycle defects.
Materials and methods

Generation of BLGmdm2/p19ARF transgenic mice
The BLGmdm2 transgenic mouse line TG3640 (Lundgren et al., 1997) was maintained in the B6C3F2 strain background in a heterozygous state. A p19ARF heterozygous male mouse in a C57BL/6-129/SV mixed strain background was generously received from Martine Roussel and Charles Sherr (St. Jude Children's Research Hospital, Memphis, Tennessee TN, USA). The p19ARF +/7 mouse was crossed with mice carrying the BLGmdm2 transgene. BLGmdm2/p19ARF +/7 mice were intercrossed to obtain p19ARF 7/7 , BLGmdm2, and BLGmdm2/p19ARF 7/7 mice.
Genotyping of mice
p19ARF homozygous mutant mice were identi®ed by PCR and by Southern blotting, as described (Sherr and Roussel, personal communication; Kamijo et al., 1997) . The primer set used for ampli®cation of the wild-type DNA was 5'- Number of mice examined AGTACAGCAGCGGGAGCATGG-3' and 5'-TTGAG-GAGGACCGTGAAGCCG-3'. For ampli®cation of the mutant DNA, the following primer set was used: 5'-TTGAGGAGGACCGTGAAGCCG-3' and 5'-ACCA-CACTGCTCGACATTGGG-3'. PCR ampli®cation was performed in a 20 ml reaction volume using 0.5 ml of a 1 : 10 dilution of tail DNA, 14 pmol/ml of primers, 2.5 mM of dNTPs, 2 ml 106Pfu buer, and 0.125 U of Pfu polymerase (Stratagene) for wild-type or Taq polymerase (Roche) for mutant. PCR ampli®cation of the wild-type band were as follows: initial cycle of 958C for 5 min followed by 35 cycles of 958C for 1 min, 708C for 1 min, 728C for 1 min, with a ®nal extension of 10 min at 728C. PCR conditions for ampli®cation of the mutant band were as follows: initial cycle of 958C for 5 min followed by 35 cycles of 958C for 1 min, 708C for 1 min, 728C for 2 min, with a ®nal extension of 10 min at 728C.
The presence of the BLGmdm2 transgene was determined by a dominant coat color marker that was coinjected with the transgene and by PCR with transgene-speci®c primers as described previously (Kucera et al., 1996; Lundgren et al., 1997) .
Histology
Age-matched nulliparous females of the appropriate genotypes were mated and sacri®ced. The following timepoints were analysed: day 10 and 15 of pregnancy, day 1, 3, 4 and 5 of lactation. The left and right sides of the abdominal mammary gland were dissected out for analysis and ®xed in 10% buered formalin. Due to low milk production in female mice carrying the BLGmdm2 transgene, pups from these females were exchanged with foster pups 3 to 5 days older to allow for continued nursing. Most mice were given an intraperitoneal injection of 100 mg of BrdU in PBS per gram of body weight 2 h before sacri®ce. Paran-embedded tissues were sectioned at 7 mm onto Superfrost-coated slides (Fisher Scienti®c). Slides were stained with H and E using standard staining procedures.
Apoptosis
Mammary gland tissue was analysed for the occurrence of apoptosis (programmed cell death) using a TUNEL (Tdtmediated dUTP-biotin nick end labeling) assay. Paranembedded slides were deparanized in a xylene to ethanol gradient. TUNEL assays followed a modi®ed protocol described in Gavrieli et al. (1992) . Slides were treated with 20 mg/ml proteinase K for 15 min. Endogenous peroxidase was inactivated by 3% hydrogen peroxide/methanol for 5 min. Slides were incubated for 2 min in terminal transferase buer containing Tris, sodium cacodylate, and cobalt chloride. Incubation in terminal transferase (Tdt) enzyme and biotin-UTP (Boehringer Mannheim/Roche) was done at 378C for 45 min. The reaction was stopped with the addition of TB buer containing sodium chloride and sodium citrate. Slides were blocked in 2% BSA (bovine serum albumin) and incubated in ABC reagent (Vectastain Kit Mouse IgG, Vector Labs). Staining was detected with diaminobenzidine (DAB) (Vector Labs) substrate according to manufacturer's instructions. Finally, slides were counterstained with Nuclear Fast Red (Vector Labs) and dehydrated through an ethanol to xylene gradient.
Immunohistochemistry
Paran-embedded sections were stained for immunoreactivity to MDM2 (9313) rabbit polyclonal using the Vectastain ABC Elite Kit (Vector Laboratories). Slides were deparanized in a xylene-to-ethanol gradient. The antigen retrieval step was done using a vegetable steamer with the slides submerged in 0.01 M citrate buer (pH 6.0) for 25 min. Slides were incubated in 3% hydrogen peroxide in order to block endogenous peroxidase activity. Slides were blocked in the appropriate serum (Vectastain kit, Vector Labs) and incubated in primary antibodies diluted in serum for 1 h at 378C in a humidity chamber. Secondary antibodies and avidin-biotin (ABC) reagent were applied (Vectastain kit, Vector Labs) according to manufacturer's instructions. Staining was detected with a DAB substrate and counterstained in Nuclear Fast Red (Vector Labs). BrdU immunostaining was performed using the BrdU staining kit (Zymed, San Francisco, CA, USA) according to the manufacturer's instructions.
Western blot analysis
Mammary tissue was homogenized on ice in a buer containing 50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), 150 mM NaCl, 1 mM EDTA, 2.5 mM ethyleneglycol-bis(b-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 0.1% Tween-20, 10% glycerol, 0.1 mM phenylmethylsulfonyl uoride (PMSF), 10 mg/ml leupeptin, 20 U/ml aprotinin, 10 mM b-glycerophophate, 1 mM NaF and 0.1 mM sodium orthovanadate. After centrifugation at 20 000 g at 48C for 1 h, a protein assay (Biorad) was performed. Equal amounts of protein were loaded on an 8% SDS ± PAGE gel. Proteins were transferred onto PVDF membrane (AmershamPharmaciaBiotech) and incubated with antisera against MDM2 (9312) at a 1 : 500 dilution. Signal was detected using the ECL kit (AmershamPharmaciaBiotech). Membranes were stripped and probed with antisera against Tubulin (Tu27B) at a 1 : 50 dilution.
